“OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject’s Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s82, https://doi.org/10.25251/skin.1.supp.81.